Table of Contents

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Bladder Cancer to Oncology Clinical Trials 17

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Bladder Cancer to Oncology Clinical Trials 21

Clinical Trials by Phase in E7 Countries 22

Clinical Trials in E7 Countries by Trial Status 23

Clinical Trials by Phase 25

In Progress Trials by Phase 26

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 32

Clinical Trials by Sponsor Type 34

Prominent Sponsors 35

Top Companies Participating in Bladder Cancer Therapeutics Clinical Trials 37

Prominent Drugs 39

Latest Clinical Trials News on Bladder Cancer 40

Nov 08, 2019: Neon Therapeutics announces updated data presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting 40

Oct 21, 2019: Bavarian Nordic reports Phase II bladder cancer trial data 40

Oct 01, 2019: Roche’s Tecentriq performs well in untreated bladder cancer 41

Sep 28, 2019: Seattle Genetics and Astellas announce results from phase 1 trial of investigational agent Enfortumab Vedotin in combination with immune therapy Pembrolizumab as first-line treatment for advanced Bladder Cancer 41

Sep 24, 2019: Constellation Pharmaceuticals advances CPI-0209 into Clinical Trials, expanding its EZH2 franchise 42

Sep 23, 2019: Roche to present new data from Tecentriq at the European Society for Medical Oncology 2019 Congress 42

Clinical Trial Profile Snapshots 44

Appendix 929

Abbreviations 929

Definitions 929

Research Methodology 930

Secondary Research 930

About GlobalData 931

Contact Us 931

Disclaimer 931

Source 932

Bladder Cancer Global Clinical Trials Review, H2, 2019

Summary

GlobalData's clinical trial report, “Bladder Cancer Global Clinical Trials Review, H2, 2019" provides an overview of Bladder Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.